Primary Care Clinics in Wellston, OK Accepting Medicare
4 Primary Care Clinics found. Showing 1 - 4
 Wellston Family Medical Clinic, Pllc Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 309 W. 2nd St., Wellston, OK 74881 Phone: 405-356-2998 Fax: 405-258-0498 |
Country Care Family Clinic, Llc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 304 W 2nd St, Wellston, OK 74881 Phone: 405-473-7053 Fax: 405-832-1144 |
Clinic At Wellston Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 309 West 2nd Street, Suite B, Wellston, OK 74881 Phone: 405-356-3035 Fax: 405-356-3035 |
Country Care Clinic Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 309 W 2nd St Ste B, Wellston, OK 74881 Phone: 405-356-3001 Fax: 405-832-1144 |
News Archive
Sapient awarded multiple-award ID/IQ prime contract with CDC
Sapient Government Services, a division of Sapient, today announced that it has been awarded a multiple-award Indefinite Delivery / Indefinite Quantity (ID/IQ) prime contract with the Centers for Disease Control and Prevention (CDC). The award allows Sapient to compete for task orders with other contract awardees to perform a variety of management consulting services for the CDC under the agency's Information Management Services (CIMS) contract.
Merck KGaA and Dyesol sign joint development agreement
Merck KGaA and Dyesol Limited have signed an agreement to collaborate in the development of electrolytes for use in Dye Solar Cells (DSC).
Meth abuse and curbs on cold medicines
As states and Congress rush to put common cold, cough and allergy drugs behind the pharmacy counter to curb illegal methamphetamine production, no one has asked consumers what they think about these restrictions - until now. Harris Interactive asked nearly 3,000 consumers about these and related issues in a national survey commissioned by the National Consumers League (NCL) and Food Marketing Institute (FMI).
Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Novel vaccine for treating heroin addiction
Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.
› Verified 8 days ago